<DOC>
	<DOCNO>NCT00089349</DOCNO>
	<brief_summary>This phase II trial study well give alemtuzumab without methotrexate mercaptopurine work treat young patient relapse acute lymphoblastic leukemia . Monoclonal antibody alemtuzumab locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy , methotrexate mercaptopurine , work different way stop cancer cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Alemtuzumab With Without Methotrexate Mercaptopurine Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate alemtuzumab alone combination methotrexate mercaptopurine child acute lymphoblastic leukemia second great relapse twice induction failure . II . Determine toxicity regimens patient . SECONDARY OBJECTIVES : I . Determine pharmacokinetics alemtuzumab patient . II . Determine immune response patient treat alemtuzumab . III . Determine change number CD52-positive cell blood marrow patient treat alemtuzumab . IV . Determine rate time clearance peripheral circulating lymphoblast patient treat regimen . OUTLINE : This multicenter study . Course 1 : Patients receive alemtuzumab IV 2 hour day 1-5 , 8 , 10 , 12 , 15 , 17 , 19 , 22 , 24 , 26 absence disease progression unacceptable toxicity . Patients achieve complete remission ( CR ) , partial remission ( PR ) , cytolytic PR day 29 , patient CNS disease achieve CNS 1 CNS 2 status , proceed course 2 . Courses 2 3 : Patients receive alemtuzumab IV 2 hour day 1 , 8 , 15 , 22 ; methotrexate IV continuously 24 hour day 1 orally daily day 8 , 15 , 22 ; oral mercaptopurine daily day 1-28 . Patients CR PR day 29 proceed course 3 . In course 3 , patient receive alemtuzumab , methotrexate , mercaptopurine course 2 . CNS prophylaxis* : Patients receive methotrexate intrathecally day 1 course 2 3 day 1 course 2 3 . NOTE : * CNS-negative patient receive methotrexate intrathecally day 15 course 1 day 1 course 2 3 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Diagnosis acute lymphoblastic leukemia ( ALL ) Meets 1 follow criterion : Second subsequent bone marrow relapse Failed ≥ 2 regimen remission induction Patients relapse receive standard ALL maintenance chemotherapy require wait period prior study entry More 25 % blast bone marrow aspirate ( M3 marrow ) CD52 expression ≥ 25 % malignant cell relapse Philadelphia chromosomepositive patient must fail prior imatinib mesylate Performance status Karnofsky 50100 % ( patient &gt; 10 year age ) Performance status Lansky 50100 % ( patient ≤ 10 year age ) At least 8 week ALT ≤ 5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min Creatinine normal age Pulse oximetry &gt; 94 % No evidence dyspnea rest No exercise intolerance No serious uncontrolled infection No autoimmune hemolytic anemia No autoimmune thrombocytopenia Not pregnant nursing No nursing 3 month study participation Negative pregnancy test Fertile patient must use effective contraception 6 month study participation Seizure disorder allow provided patient anticonvulsant symptom well control CNS toxicity ≤ grade 2 No serious uncontrolled medical condition ( e.g. , diabetes ) Recovered prior immunotherapy At least 8 week since prior biologic agent ( e.g. , monoclonal antibody ) More 1 week since prior growth factor ( ) At least 4 month since prior stem cell transplantation No evidence active acute chronic graftversushost disease post allogeneic stem cell transplantation No prior alemtuzumab component No concurrent anticancer immunomodulating agent Recovered prior chemotherapy One dose prior intrathecal ( IT ) methotrexate , cytarabine , hydrocortisone ; IT cytarabine alone ; IT methotrexate alone allow part initial diagnostic spinal tap Prior hydroxyurea therapy allow No concurrent anticancer chemotherapy agent Prior steroid therapy allow More 2 week since prior radiotherapy recover</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>